Small conformationally restricted piperidine N-arylsulfonamides as orally active gamma-secretase inhibitors.

The design and development of a new class of small 2,6-disubstituted piperidine N-arylsulfonamide gamma-secretase inhibitors is reported. Lowering molecular weight including the use of conformational constraint led to compounds with less CYP 3A4 liability compared to early leads. Compounds active orally in lowering Abeta levels in Tg CRND8 mice were identified as potential treatments for Alzheimer's disease.

[1]  I. Churcher,et al.  γ-Secretase as a Therapeutic Target for the Treatment of Alzheimers Disease , 2005 .

[2]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[3]  O. Kulinkovich,et al.  Titanium(IV) Isopropoxide-Catalyzed Formation of 1-Substituted Cyclopropanols in the Reaction of Ethylmagnesium Bromide with Methyl Alkanecarboxylates , 1991 .

[4]  R. Vassar.  The beta-secretase, BACE: a prime drug target for Alzheimer's disease. , 2001, Journal of molecular neuroscience : MN.

[5]  C. Haass,et al.  N-Substituted carbazolyloxyacetic acids modulate Alzheimer associated γ-secretase , 2007 .

[6]  Timothy Harrison,et al.  The Novel γ Secretase Inhibitor N-[cis-4-[(4-Chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) Reduces Amyloid Plaque Deposition without Evidence of Notch-Related Pathology in the Tg2576 Mouse , 2007, Journal of Pharmacology and Experimental Therapeutics.

[7]  Bu Hz,et al.  A literature review of enzyme kinetic parameters for CYP3A4-mediated metabolic reactions of 113 drugs in human liver microsomes: structure-kinetics relationship assessment. , 2006 .

[8]  Johan Lundkvist,et al.  γ-Secretase: a complex target for Alzheimer's disease , 2007 .

[9]  D. Selkoe,et al.  The origins of Alzheimer disease: a is for amyloid. , 2000, JAMA.

[10]  Zhang Zy,et al.  Enzyme Kinetics for Clinically Relevant CYP Inhibition , 2005 .

[11]  W. Greenlee,et al.  Discovery of γ-secretase inhibitors efficacious in a transgenic animal model of Alzheimer’s disease , 2007 .

[12]  村橋 俊一.  Ruthenium in organic synthesis , 2004 .

[13]  M. Pallàs,et al.  Molecular and biochemical features in Alzheimer's disease. , 2006, Current pharmaceutical design.

[14]  D. Barton,et al.  A new method for the deoxygenation of secondary alcohols , 1975 .

[15]  Robert A. Dean,et al.  Effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer disease , 2006, Neurology.

[16]  C. Masters,et al.  Inhibition of γ-Secretase as a Therapeutic Intervention for Alzheimer’s Disease , 2006 .

[17]  G. Cignarella,et al.  Bicyclic Homologs of Piperazine. II. Synthesis of 3,8-Diazabicyclo[3.2.1]octane. New Synthesis of 8-Methyl-3,8-diazabicyclo[3.2.1]octane , 1961 .

[18]  M. Wolfe,et al.  Secretase targets for Alzheimer's disease: identification and therapeutic potential. , 2001, Journal of medicinal chemistry.

[19]  Shufeng Zhou,et al.  Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4 , 2005, Therapeutics and clinical risk management.

[20]  R. J. Riley,et al.  Development of a Generalized, Quantitative Physicochemical Model of CYP3A4 Inhibition for Use in Early Drug Discovery , 2001, Pharmaceutical Research.

[21]  Maurice Dickins,et al.  Quantitative structure–activity relationships (QSARs) in CYP3A4 inhibitors: The importance of lipophilic character and hydrogen bonding , 2006, Journal of enzyme inhibition and medicinal chemistry.

[22]  S. Conde.  β-Amyloid peptide as a target for treatment of Alzheimer’s disease , 2002 .

[23]  W. Greenlee,et al.  2,6-Disubstituted N-arylsulfonyl piperidines as γ-secretase inhibitors , 2007 .